Toward personalized therapy in AML: In vivo benefit of targeting aberrant epigenetics in MLL-PTD-associated AML

K. M. Bernot, R. F. Siebenaler, S. P. Whitman, N. A. Zorko, G. G. Marcucci, R. Santhanam, E. H. Ahmed, M. Ngangana, K. K. McConnell, J. S. Nemer, D. L. Brook, S. K. Kulp, C. S. Chen, D. Frankhouser, P. Yan, R. Bundschuh, X. Zhang, A. M. Dorrance, K. E. Dickerson, D. JarjouraW. Blum, G. Marcucci, M. A. Caligiuri

Research output: Contribution to journalLetter

11 Scopus citations
Original languageEnglish (US)
Pages (from-to)2379-2382
Number of pages4
JournalLeukemia
Volume27
Issue number12
DOIs
StatePublished - Dec 1 2013

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Bernot, K. M., Siebenaler, R. F., Whitman, S. P., Zorko, N. A., Marcucci, G. G., Santhanam, R., Ahmed, E. H., Ngangana, M., McConnell, K. K., Nemer, J. S., Brook, D. L., Kulp, S. K., Chen, C. S., Frankhouser, D., Yan, P., Bundschuh, R., Zhang, X., Dorrance, A. M., Dickerson, K. E., ... Caligiuri, M. A. (2013). Toward personalized therapy in AML: In vivo benefit of targeting aberrant epigenetics in MLL-PTD-associated AML. Leukemia, 27(12), 2379-2382. https://doi.org/10.1038/leu.2013.147